Table 2.
Underlying conditions and clinical findings in patients with COVID-19 pneumonia in the non-B.1.1.7 group.
| Variables | Community-acquired pneumonia | Nursing and healthcare-associated pneumonia | p value |
|---|---|---|---|
| No. of patients | 422 | 79 | |
| Median age (IQR), years | 62 (41–73) | 80 (70–85) | <0.0001 |
| No. of males/females | 263/159 | 48/31 | 0.8015 |
| No. (%) of patients with comorbid illnesses | |||
| Diabetes mellitus | 82 (19.4) | 21 (26.6) | 0.1717 |
| Chronic lung disease | 45 (10.7) | 12 (15.2) | 0.2485 |
| Chronic heart disease | 20 (4.7) | 20 (25.3) | <0.0001 |
| Cerebrovascular disease | 15 (3.6) | 17 (21.5) | <0.0001 |
| Chronic renal disease | 17 (4.0) | 15 (19.0) | <0.0001 |
| Neoplastic disease | 17 (4.0) | 14 (17.7) | <0.0001 |
| Chronic liver disease | 11 (2.6) | 4 (5.1) | 0.2723 |
| Autoimmune disease | 13 (3.2) | 2 (2.5) | >0.9999 |
| No. (%) of patients with the following clinical signs and symptoms | |||
| History of fever (≥37.0 °C) | 351 (83.2) | 71 (89.9) | 0.1773 |
| Cough | 224 (53.1) | 29 (36.7) | 0.0097 |
| Fatigue | 152 (36.0) | 17 (21.5) | 0.0135 |
| Shortness of breath | 117 (27.7) | 21 (26.6) | 0.8915 |
| Sore throat | 93 (22.0) | 4 (5.1) | 0.0002 |
| Loss of taste | 62 (14.7) | 4 (5.1) | 0.0180 |
| Anosmia | 51 (12.1) | 3 (3.8) | 0.0287 |
| Headache | 52 (12.3) | 2 (2.5) | 0.0088 |
| Diarrhea | 47 (11.1) | 4 (5.1) | 0.1089 |
| Sputum production | 41 (9.7) | 8 (10.1) | 0.8389 |
| Runny nose | 35 (8.3) | 1 (1.3) | 0.0292 |
| Joint pain | 28 (6.6) | 0 | 0.0134 |
| Chest pain | 17 (4.0) | 1 (1.3) | 0.3315 |
| Muscle ache | 16 (3.8) | 1 (1.3) | 0.4939 |
| Nausea or vomiting | 13 (3.1) | 4 (5.1) | 0.3241 |
| Abdominal pain | 5 (1.2) | 1 (1.3) | >0.9999 |
| No. (%) of patients with each pneumonia severity score | |||
| 0 | 195 (46.2) | 2 (2.5) | <0.0001 |
| 1 | 111 (26.3) | 18 (22.8) | 0.5764 |
| 2 | 74 (17.5) | 36 (45.6) | <0.0001 |
| 3 | 29 (6.9) | 23 (29.1) | <0.0001 |
| 4 | 9 (2.1) | 0 | 0.3665 |
| 5 | 4 (0.9) | 0 | >0.9999 |
| No. (%) of patients with treatment | |||
| Antibiotic therapy | 131 (31.0) | 60 (75.9) | <0.0001 |
| Antiviral therapy | 247 (58.5) | 77 (97.5) | <0.0001 |
| Glucocorticoid therapy | 183 (43.4) | 64 (81.0) | <0.0001 |
| No. (%) of patients with respiratory care | |||
| HFNC | 116 (27.5) | 18 (22.8) | 0.410 |
| IMV | 96 (22.7) | 38 (48.1) | <0.0001 |
| ECMO | 25 (5.9) | 10 (12.7) | 0.049 |
| No. (%) of patients admitted to intensive care unit | 121 (28.7) | 48 (60.8) | <0.0001 |
| No. (%) of patients with in-hospital mortality | 7 (1.7) | 15 (19.0) | <0.0001 |
Continuous values are presented as medians and interquartile ranges (IQRs) and categorical/binary values as counts and percentages. HFNC, high flow nasal canula. IMV, invasive mechanical ventilation. ECMO, extracorporeal membrane oxygen.